Immunotherapy for esophageal cancer: A 2019 update

Dimitrios Schizas; Nikolaos Charalampakis; Christo Kole; Konstantinos S. Mylonas; Ioannis Katsaros; Meina Zhao; Jaffer A. Ajani; Amanda Psyrri; Michalis V. Karamouzis; Theodore Liakakos

doi:10.2217/imt-2019-0153

Immunotherapy for esophageal cancer: A 2019 update

Dimitrios Schizas, Nikolaos Charalampakis, Christo Kole, Konstantinos S. Mylonas, Ioannis Katsaros, Meina Zhao, Jaffer A. Ajani, Amanda Psyrri, Michalis V. Karamouzis, Theodore Liakakos

GI Medical Oncology

Research output: Contribution to journal › Review article › peer-review

30 Scopus citations

Abstract

Esophageal cancer remains a global health concern with a dismal prognosis and an estimated 5-year survival rate of approximately 10-15%. Immunotherapy is a novel treatment approach representing an effective and promising option against several types of cancer. The development of new and efficacious immunotherapeutic strategies, such as adoptive cell therapy-based, antibody-based and vaccine-based therapies, aims to prevent immunological escape and modify immunological responses. In this review, we discuss the theoretical background and current status of immunotherapy for patients with esophageal cancer. We also present ongoing clinical trials and summarize key findings concerning survival and safety analyses.

Original language	English (US)
Pages (from-to)	203-218
Number of pages	16
Journal	Immunotherapy
Volume	12
Issue number	3
DOIs	https://doi.org/10.2217/imt-2019-0153
State	Published - Feb 2020

Keywords

adoptive cell transfer
cancer vaccines
checkpoint inhibitors
esophageal cancer
immunotherapy
tumor infiltrating lymphocytes

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.2217/imt-2019-0153

Cite this

@article{e831a4f376f54690a3766b44bf580267,

title = "Immunotherapy for esophageal cancer: A 2019 update",

abstract = "Esophageal cancer remains a global health concern with a dismal prognosis and an estimated 5-year survival rate of approximately 10-15%. Immunotherapy is a novel treatment approach representing an effective and promising option against several types of cancer. The development of new and efficacious immunotherapeutic strategies, such as adoptive cell therapy-based, antibody-based and vaccine-based therapies, aims to prevent immunological escape and modify immunological responses. In this review, we discuss the theoretical background and current status of immunotherapy for patients with esophageal cancer. We also present ongoing clinical trials and summarize key findings concerning survival and safety analyses.",

keywords = "adoptive cell transfer, cancer vaccines, checkpoint inhibitors, esophageal cancer, immunotherapy, tumor infiltrating lymphocytes",

author = "Dimitrios Schizas and Nikolaos Charalampakis and Christo Kole and Mylonas, {Konstantinos S.} and Ioannis Katsaros and Meina Zhao and Ajani, {Jaffer A.} and Amanda Psyrri and Karamouzis, {Michalis V.} and Theodore Liakakos",

note = "Publisher Copyright: {\textcopyright} 2020 Future Medicine Ltd.",

year = "2020",

month = feb,

doi = "10.2217/imt-2019-0153",

language = "English (US)",

volume = "12",

pages = "203--218",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Future Medicine Ltd.",

number = "3",

}

TY - JOUR

T1 - Immunotherapy for esophageal cancer

T2 - A 2019 update

AU - Schizas, Dimitrios

AU - Charalampakis, Nikolaos

AU - Kole, Christo

AU - Mylonas, Konstantinos S.

AU - Katsaros, Ioannis

AU - Zhao, Meina

AU - Ajani, Jaffer A.

AU - Psyrri, Amanda

AU - Karamouzis, Michalis V.

AU - Liakakos, Theodore

PY - 2020/2

Y1 - 2020/2

N2 - Esophageal cancer remains a global health concern with a dismal prognosis and an estimated 5-year survival rate of approximately 10-15%. Immunotherapy is a novel treatment approach representing an effective and promising option against several types of cancer. The development of new and efficacious immunotherapeutic strategies, such as adoptive cell therapy-based, antibody-based and vaccine-based therapies, aims to prevent immunological escape and modify immunological responses. In this review, we discuss the theoretical background and current status of immunotherapy for patients with esophageal cancer. We also present ongoing clinical trials and summarize key findings concerning survival and safety analyses.

AB - Esophageal cancer remains a global health concern with a dismal prognosis and an estimated 5-year survival rate of approximately 10-15%. Immunotherapy is a novel treatment approach representing an effective and promising option against several types of cancer. The development of new and efficacious immunotherapeutic strategies, such as adoptive cell therapy-based, antibody-based and vaccine-based therapies, aims to prevent immunological escape and modify immunological responses. In this review, we discuss the theoretical background and current status of immunotherapy for patients with esophageal cancer. We also present ongoing clinical trials and summarize key findings concerning survival and safety analyses.

KW - adoptive cell transfer

KW - cancer vaccines

KW - checkpoint inhibitors

KW - esophageal cancer

KW - immunotherapy

KW - tumor infiltrating lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=85082874577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85082874577&partnerID=8YFLogxK

U2 - 10.2217/imt-2019-0153

DO - 10.2217/imt-2019-0153

M3 - Review article

C2 - 32208794

AN - SCOPUS:85082874577

SN - 1750-743X

VL - 12

SP - 203

EP - 218

JO - Immunotherapy

JF - Immunotherapy

IS - 3

ER -

Immunotherapy for esophageal cancer: A 2019 update

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this